The secondary end point of change in free-living daily step
activity measured by pedometer use, biomarkers, and QOL indicators
was assessed by pairwise ANCOVA with adjustment for
baseline cilostazol use and study center but with a 2-sided significance
level of 0.05 for each comparison without adjustment for
multiple comparisons. Pedometer activity was normalized to steps
per hour to account for differences in hours of pedometer use during
the assessment period. All analyses were conducted according to the
intention-to-treat principle. Results were based on available data.
Multiple imputation of missing primary end point data was also
performed.